SREBF1 and fatty liver disease: Thus, FGF19 and NGM282 appear to selectively modulate LXR signaling, upregulating canonical LXR target genes (Abcg5, Abcg8, Scarb1, Srebf1, Fasn, Scd1, Srebf2, and Scap) without inducing hepatic steatosis.